Clinical Lymphoma Myeloma & Leukemia

Papers
(The median citation count of Clinical Lymphoma Myeloma & Leukemia is 0. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-11-01 to 2025-11-01.)
ArticleCitations
SOHO State of the Art Updates and Next Questions | Approach to BCR::ABL1-Like Acute Lymphoblastic Leukemia74
Corrigendum to “OAB-005: Update of safety and efficacy of Isatuximab short-duration fixed-volume infusion plus Bortezomib, Lenalidomide, and Dexamethasone combined therapy for NDMM ineligible/with no 37
P-112 Fall Risk Assessment and Fall Prevention in Patients With Multiple Myeloma: First Results of the MYFALL-Trial36
P-186 Identifying a New Risk-Stratification Strategy by Including Single-Cell Biomarkers in Multiple Myeloma35
P-154 Multidisciplinary, Patient-Centric Bone Disease Management in Multiple Myeloma – a Single-Centre Experience35
P-202 Risk Factors Predicting Early Relapse for Newly Diagnosed Multiple Myeloma Patients Treated with Front-Line VRD Regimen31
P-330 Stem Cell Mobilization Strategy With Pegilgrastim for Stem Cell Transplantation for Multiple Myeloma: A Direct Cost Comparison30
P-309 Diagnostic Challenges in Systemic Amyloidosis: Exploring the Impact of Mass Spectrometry in a Middle-Income Country Cohort28
P-232 Comprehensive Genomic Sequencing Predicts Sub-Optimal Response to Bispecific Antibodies (BsAb) and Chimeric Antigen Receptor T Cells (CAR-T) in Multiple Myeloma (MM)27
P-342 Impact of Achieving <VGPR With Dara-RVD Induction Therapy in Newly Diagnosed Multiple Myeloma (NDMM) Patients26
P-012 Real-World Safety and Early Efficacy of Talquetamab in Patients with Heavily-Pretreated Relapsed/Refractory Multiple Myeloma25
OA-27 Para-Medullary (PMD) and Extra-Medullary (EMD) Myeloma Demonstrate Increased Copy Number Aberration, Mutational Burden, Structural Variants and Genomic Complexity Compared to Marrow-Based Myelom25
P-068 Developing Novel DKK1-A2 CAR-T Cell Therapy for Myeloma and Other Hematologic Malignancies25
P-113 An Artificial Intelligence-Based 3D-Segmentation Assessment of Sarcopenia Utilizing Whole-Body Computed Tomography in Patients With Multiple Myeloma24
P-455 Survey of multiple myeloma (MM) patients and healthcare professionals (HCPs) on the relevance of existing health quality-of-life (QoL) questionnaires (QoLQ) to real-world QoL issues of MM patien23
P-100 Prevalence of monoclonal gammopathies in adult Uruguayan population23
P-139 Impact of melphalan staggered dosing prior to autologous hematopoietic cell transplantation for multiple myeloma patients21
OA-38 Physical activity interventions to improve functional performance in patients with multiple myeloma21
MM-731 Prognostic Implications of Immune Paralysis in Newly Diagnosed Multiple Myeloma20
MPN-153 A Phase 1b Trial of DISC-0974, an Antihemojuvelin Antibody, in Participants With Myelofibrosis and Anemia20
Management Challenges in Patients with Treatment-Free Remission of Chronic Myeloid Leukemia20
Demographic Characteristics of Hospitalized Patients With History of Multiple Myeloma in Remission: Insights From National Inpatient Sample 202120
IBCL-381 Studying the Impact of CD38 Expression on Extracellular Adenosine and Its Connection With the PD1/PDL1 Axis in Mature B-Cell Lymphoma Patients19
MM-542 Patient-Reported Outcomes From the DREAMM-7 Randomized Phase 3 Study Comparing Belantamab Mafodotin (Belamaf), Bortezomib, and Dexamethasone vs Daratumumab Bortezomib, and Dexamethasone in Pati19
Utility of CNS Prophylaxis in Diffuse Large B-Cell Lymphoma Patients – A Single Institution Experience From Pakistan19
ABCL-440 Preliminary Safety and Efficacy Data of Combination Polatuzumab Vedotin Rituximab, Cyclophosphamide Adriamycin, Prednisone (Pola-R-CHP) in Patients With Diffuse Large B-Cell Lymphoma (DLBCL) 19
CT-244 Updated Clinical Progress of IL-10 expressing CD19 CAR-T Cells for Treatment of Relapsed or Refractory B-Cell Hematological Malignancies at Tiny Doses19
MM-597 Diarrhea in Multiple Myeloma Autologous Stem Cell Transplant Recipients: Think Beyond Mucositis18
Frequency of Practice-Changing Findings Identified by Comprehensive Genomic Profiling in Non-Myeloid Hematologic Malignancies18
MPN-307 Systemic AA Amyloidosis as a Complication of Idiopathic Multicentric Castleman's Disease17
Barriers to Receiving Allogeneic Hematopoietic Cell Transplantation for Acute Myeloid Leukemia: Insights From a Large-Scale Multicenter Observational Study17
Idecabtagene Vicleucel (Ide-Cel) Versus Standard Regimens (SRs) in Triple-Class–Exposed (TCE) Relapsed and Refractory Multiple Myeloma (RRMM): KarMMa-3 Sub-Analysis of Black Patients17
Therapeutic Efficacy of Acupuncture Combined With Pharmacology in Bortezomib-Induced Peripheral Neuropathy17
Evaluating the Impact of an Electronic Medical Record (EMR) Alert on Appropriate Dosing of Luspatercept in Patients With Lower-Risk Myelodysplastic Syndromes (LR-MDS) in a Community Oncology Network16
ALL-441 Outcome of Adult Acute Lymphoblastic Leukemia, a Single-Center Experience16
CLL-656 Multiplex ligation-dependent probe amplification (MLPA): Utility as a first line screening tool for detection of clinically relevant genomic aberrations in CLL16
CML-674 Molecular Screening of Tyrosine Kinase Inhibitor Resistance in Tunisian Patients With Chronic Myeloid Leukemia16
Time-Dependent Transfusion Status as an Independent Predictor of Overall Survival: A Post Hoc Analysis of 3 Phase 3 Trials15
CML-627 Concomitant Acid-Reducing Agents With TKI Increases Time to Achieve Remission in Patients With CML: A Real-World Analysis of a US Claims Database15
Dose-Adjusted Melphalan Yields Comparable MRD-Negativity to Full-Dose Melphalan in Multiple Myeloma Patients Undergoing Autologous Stem Cell Transplant15
MM-645 Updated OS of Patients With AL Amyloidosis After CAEL-10115
CT-175 The Impact of Diabetes Mellitus on Hematopoietic Stem Cell Mobilization15
Influence of Heart Failure Upon Incidence Rates of Pneumonia, Acute Respiratory Failure, Sepsis and Septic Shock in Patients With Polycythemia Vera14
Accessing BTK Inhibitors and Other Novel Therapies for Mantle Cell Lymphoma: Are We All Invited to the Party?14
Treatment Patterns, Efficacy, and Tolerability of Belantamab Mafodotin in Patients With Relapsed and/or Refractory Multiple Myeloma: A Real-World Analysis14
Olutasidenib Demonstrates Promising Tolerability and Efficacy in IDH1-Mutated Accelerated/Blast-Phase Myeloproliferative Neoplasms14
Higher Relapse Rate and Resource Utilization With Ara-C Consolidation Chemotherapy Alone Compared With Hematopoietic Cell Transplantation in First Remission in a Cohort of Younger Adults With Acute My14
Outcomes of Bone Marrow Transplant in ESRD vs Non-ESRD Patients: A Nationwide Analysis14
Association Between Hemoglobin Improvement and Patient-Reported Outcomes in Patients With Myelofibrosis and Anemia: Post Hoc Pooled Analysis of Momelotinib Phase 3 Trials14
Limited Toxicity and Impressive Outcomes of Upfront Flag-Based Induction in Newly Diagnosed Acute Myeloid Leukemia: An Indian Scenario14
Efficacy and Safety of Ciltacabtagene Autoleucel ± Lenalidomide Maintenance in Newly Diagnosed Multiple Myeloma With Suboptimal Response to Frontline Autologous Stem Cell Transplant: CARTITUDE-2 Cohor14
Real-World Comparison of Carfilzomib, Lenalidomide, and Dexamethasone Versus Ixazomib, Lenalidomide, and Dexamethasone in Patients With Relapsed/Refractory Multiple Myeloma: KMM2004 Study14
MDS-570 NPM1-Mutated Myeloid Neoplasms Irrespective of Blast Count Are Associated With Better Outcomes With Acute Myeloid Leukemia Treatment Approach13
Epidemiological Profile and Outcomes of Patients Admitted to the Intensive Care Unit at Yeolyan Hematology and Oncology Center: A Retrospective Study13
IBCL-541 A Comprehensive Single-Cell Multi-Omic Analysis to Depict the Biological Heterogeneity of Follicular and Large B-Cell Lymphomas13
Phase 3 BELLWAVE-010: Nemtabrutinib Plus Venetoclax Versus Venetoclax Plus Rituximab (VR) in Relapsed or Refractory (R/R) Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)13
P-067 Long-Term Follow-Up From the Phase 1/2 MajesTEC-1 Trial of Teclistamab in Patients With Relapsed/Refractory Multiple Myeloma13
Management of Patients with Lower-Risk Myelodysplastic Syndromes (LR-MDS) in a Large US Community Oncology Practice: A Focus on Patient Outcomes Post Erythropoiesis-Stimulating Agent (ESA) Treatment13
Neurolymphomatosis: An Unusual Manifestation of Relapsed/Refractory Lymphoma13
Monoclonal Insulin Autoimmune Syndrome Successfully Treated With Plasma Cell Directed Therapy13
P-383 A 16-gene signature reflecting tumor microenvironment predicts the risk of multiple myeloma patients treated by bortezomib-based therapies12
P-266 Pre-clinical characterization of SAR442257, a CD38xCD28xCD3 trispecific T-cell engager in relapsed/refractory multiple myeloma12
P-309 ZnDDC, a novel CELMoD-like agent binding to DDB1-CRBN complex demonstrates significant synergism with BTZ and IMiDs and overcomes IMiDs resistance in myeloma cell lines and primary samples12
Editorial Board12
Characterization and Outcomes of Spanish Patients With Relapsed/Refractory Multiple Myeloma Included in the LocoMMotion Study12
POSTER: TCL-196 Hepatosplenic T-Cell Lymphoma in Adolescents and Young Adults: A Case Report12
P-138 Real World Single Centre Experience On The Use of Radiotherapy In The Treatment of Patients with Multiple Myeloma12
P-378 Longitudinal antibody and T-cell kinetics over four doses of COVID-19 vaccination and predictors of poor response in patients with multiple myeloma12
Expert Opinion on Multiple Myeloma Treatment in Brazil in the Bispecific Antibody Era12
OA-08 GPRC5D-targeted CAR-T cell therapy in patients with relapsed or refractory multiple myeloma progressing after or refractory to BCMA CAR-T cell therapy: updated eesults from a phase 2 clinical tr12
Delphi Survey on Measurable Residual Disease in Multiple Myeloma: Prevailing Practices and the Way Forward in India12
Impact of Facility Type on Survival in Chronic Myelomonocytic Leukemia: A Propensity Score Matched, National Cancer Database Analysis12
POSTER: AML-132 QuANTUM-First Trial: FLT3–Internal Tandem Duplication (FLT3-ITD)–Specific Measurable Residual Disease (MRD) Clearance Is Associated With Improved Overall Survival (OS)12
P-200 MAP4K2 inhibition reinforces sensitivity to iberdomide in RAS-mutated MM through a CRBN-independent mechanism12
OA-22 TiMMing: developing an innovative suite of bioinformatic tools to harmonize and track the origin of copy number alterations in the evolutionary history of multiple myeloma12
P-278 Estimating the size of patients with relapsed/ refractory multiple myeloma treated with 1-3 and 4 or more prior lines of therapy in the United States12
P-361 Genomic and transcriptomic landscape of hyper-APOBEC multiple myeloma12
P-314 Daratumumab for Refractory Proliferative Glomerulonephritis With Monoclonal Immunoglobulin G Deposits and Severe Chronic Kidney Disease12
Treatment Options for Patients With Heavily Pretreated Relapsed and Refractory Multiple Myeloma12
Evaluating Response Trends of Chlormethine/Mechlorethamine Gel in Patients With Stage I-IIA Mycosis Fungoides: Analysis of Individual Patient Data From a Randomized Controlled Phase II Study to Facili12
CML-062 Define the Vulnerable - Social Determinants of Health Impact on Hematological Malignancies Affecting Children, Adolescents, and Young Adults: Systematic Review and Meta-Analysis11
ABCL-181 Germinal Center Double Hit Diffuse Large B-Cell Lymphoma Refractory to Chemoimmunotherapy: A Case Report11
POSTER: ABCL-039 Metformin in Combination With the Standard Therapy in Patients With Diffuse Large B-Cell Lymphoma: A Randomized Phase II Clinical Trial11
ABCL-269 Secondary Central Nervous System (CNS) Involvement in Diffuse Large B Cell Lymphoma (DLBCL): Ten-Year Outcomes From Mexico's National Cancer Institute11
POSTER: MPN-183 Interferon Treatment Suppresses In Vitro NETosis in Neutrophils Derived from Patients With Myeloproliferative Neoplasms11
MM-508 Belantamab Mafodotin for Relapsed or Refractory Multiple Myeloma: A Real-World Observational Study Update11
POSTER: AML-112 Impact of Consolidation Chemotherapy Intensity Before Allogeneic Hematopoietic Stem Cell Transplantation in Elderly Patients With Acute Myeloid Leukemia11
POSTER: CT-127 Evaluation of Cytomegalovirus Infection/Disease Frequency and Risk Factors Following Allogeneic Stem Cell Transplantation: A Single Center Experience11
POSTER: HL-603 Hodgkin Lymphoma in Tripoli University Hospital Libya11
POSTER: MDS-145 A Successful Treatment of Relapsed/Refractory MDS Patient who is Followed Under Hemodialysis11
POSTER: AML-331 Utility of Echocardiogram in Neutropenic Patients With Gram Positive Bacteremia – A Retrospective Study11
POSTER: AML-260 A Metabolically Optimized, Non-Cytotoxic Low-Dose Weekly Decitabine/Venetoclax Regimen in MDS and AML11
POSTER: ALL-020 Localized and Generalized Lymphadenopathy Referred to 3 Tertiary Pediatric Centers Over 6 Years: The Alarming Signs11
POSTER: MPN-628 Surpass-ET: Ropeginterferon Alfa-2b (P1101) vs Anagrelide as Second Line Therapy in Essential Thrombocythemia11
MCL-179 TP53 Gene Mutations in Russian Patients With Mantle Cell Lymphoma (MCL)11
AML-396 Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN): Initial Results of a Novel, Ongoing BPDCN International Registry Program11
POSTER: ABCL-222 Diffuse Large Cell Lymphoma of the Uterus Presented With Vaginal Bleeding: A Case Report11
POSTER: HL-281 Treatment of Relapsed Hodgkin Lymphoma With Pembrolizumab as Monotherapy11
MPN-628 Surpass-ET: Ropeginterferon Alfa-2b (P1101) vs Anagrelide as Second Line Therapy in Essential Thrombocythemia10
POSTER: AML-369 Outpatient-Based Low-intensity Induction With Sorafenib in FLT3-ITD-Mutated Newly Diagnosed Acute Myeloid Leukemia (AML)10
Ixazomib With or Without Rituximab Following Maintenance Autologous Stem Cell Transplant in Mantle Cell Lymphoma: A Single-Center Phase I Trial10
CT-009 Prognostic Role of Lymphocyte to Monocyte Ratio in PTS Treated With CAR-T for Aggressive Lymphoma10
IBCL-297 Phase 2 Study of Nivolumab in Epstein-Barr Virus (EBV)-Positive Lymphoproliferative Disorders (LPD) and EBV-Positive Non-Hodgkin Lymphomas (NHL)10
Table of Contents10
POSTER: ALL-553 Unexplained Increase in Incidence of T-Acute Lymphoblastic Leukemia/Lymphoma in Armenia10
POSTER: ABCL-142 Efficacy and Safety of Single-Agent Blinatumomab as Salvage Therapy in Relapsed/Refractory B Cell Acute Lymphoblastic Leukemia (B-ALL): Real-Life Experience10
POSTER: MPN-498 Addition of Navitoclax to Ruxolitinib for Myelofibrosis Patients With Relapsed/Refractory Disease and Suboptimal Response to Ruxolitinib Monotherapy: REFINE Cohort 1 Dose Escalation an10
P-097: A novel anti-BCMA lipid-based nanoparticle for multiple myeloma therapy10
POSTER: TCL-154 STAT3 Mutations are Associated With Differential Treatment Responses to Methotrexate and Cyclophosphamide in T-Large Granular Lymphocyte Leukemia10
POSTER: MDS-156 Pyrimethamine Shows Synergy and Efficacy in Combination With Venetoclax in Preclinical Models of Therapy Resistant MDS/AML10
MM-125 Adipose Tissue Metabolic Activity in Multiple Myeloma10
POSTER: MPN-193 Incidence of Blast Phase in Myelofibrosis According to Anemia Severity10
AML-446 Time to Resolution of Myelosuppression and Associated Hospitalization in Patients With Newly-Diagnosed Acute Myeloid Leukemia (AML) Treated With Ivosidenib (IVO) + Azacitidine (AZA) Compared t10
ALL-606 A Comprehensive Retrospective Analysis of Cases from 2020-2022 in Children With Relapsed Acute Leukemia: Temporal Trends and Clinical Characteristics10
P-141: Prognostic impact of CD3/CD34 ratio in apheresis collection in multiple myeloma patients undergoing autologous stem cell transplant10
AML-013 Differences in Length of Stay Between De novo Diagnosed and Transferred Patients With Acute Myeloid Leukemia in a Community Hospital10
P-020: PD1-based chimeric-switch receptor expressing NK cells recover from immune checkpoint inhibition in cancer10
Factors Influencing Physician Discretion to Administer CNS Prophylaxis in Diffuse Large B Cell Lymphoma: A Single Institution Retrospective Study10
POSTER: CT-166 Long-Term Safety With ≥12 Months of Pirtobrutinib in Relapsed/Refractory B-Cell Malignancies10
OAB-053: Mezigdomide (MEZI; CC-92480) in combination with dexamethasone (DEX) and bortezomib (BORT) or carfilzomib (CFZ) in patients (pts) with relapsed/refractory multiple myeloma (RRMM)9
POSTER: MM-638 Role of the Combination of FDG-PET plus Whole Body MRI for Staging Newly Diagnosed and Relapsed/Refractory Multiple Myeloma (MM): A Prospective Trial9
EXABS-161-MPN Management of Pre-Fibrotic Primary Myelofibrosis9
Safety, Feasibility, and Efficacy of Exercise Interventions for People With Multiple Myeloma: A Systematic Review9
Generic Lenalidomide Rivelime Versus Brand-name Revlimid® in the Treatment of Relapsed/Refractory Multiple Myeloma: A Retrospective Single-center Experience on Efficacy, Safety and Survival Outcome9
Association Of -308G/A, -238G/A TNF-α Polymorphisms with Multiple Myeloma Risk and Survival: A Systematic Review and Meta-Analysis9
AML-271 Acute Stroke Secondary to Patent Foramen Ovale (PFO) in Patients With Acute Myeloid Leukemia (AML)9
AML-194 Second Hematological Malignancies in Survivors of Breast Cancer: An Indian Institutional Analysis9
AML-053 Assessment of Minimal Residual Disease in Patients With Adult Acute Myeloid Leukemia: Single Egyptian Center Experience9
P-212: Quantifying the average treatment effect of single vs. tandem autologous stem cell transplantation in newly diagnosed multiple myeloma using causal inference9
OAB-056: Early, deep, and durable responses, and low rates of cytokine release syndrome with REGN5458, a BCMAxCD3 bispecific antibody, in a Phase 1/2 study in patients with relapsed/refractory multipl9
Peripheral Blood Involvement at Staging in Patients With Aggressive Peripheral T-Cell Lymphoma9
MM-341 Clinical Characteristics and Risk of Progression in Patients With Monoclonal Gammopathy of Uncertain Significance (MGUS): Long-Term Experience in a Single Tertiary Hospital9
Recent Advances in the Use of Chimeric Antigen Receptor–Expressing T-Cell Therapies for Treatment of Multiple Myeloma9
P-247: Addressing the knowledge gap to optimize treatment sequencing for patients with relapsed/refractory multiple myeloma9
Hyperfractionated Cyclophosphamide and Dexamethasone Alone or in Combination with Daratumumab and/or Carfilzomib for the Treatment of Relapsed or Refractory Multiple Myeloma: A Single-Center Retrospec9
Poster: CT-132 Outcome of Sex-Mismatched Allogeneic Hemopoietic Stem Cell Transplantation from Human Leukocyte Antigen–Identical Sibling Donors in Patients With Hematologic Diseases9
Diffuse Large B Cell Lymphoma in Patients 80 Years and Older: Worse Survival After Treatment Without Increased Relapse Rates8
Poster: MPN-238 Single-Cell RNA Profiling of Myelofibrosis Patients Reveals Pelabresib-Induced Decrease of Megakaryocytic Progenitors and Normalization of CD4+ T Cells in Peripheral Blood8
ALL-004 Philadelphia Chromosome-Positive T-Cell Acute Lymphoblastic Leukemia/Lymphoblastic Lymphoma: A Rare Case Report8
MPN-469 Rusfertide (PTG-300) Treatment Interruption Reverses Hematological Gains and Upon Reinitiation, Restoration of Clinical Benefit Observed in Patients With Polycythemia Vera8
Poster: MM-198 Anti-BCMA Therapy in Multiple Myeloma: A Single-Center Experience8
Poster: CT-227 Dual CAR-Engineered NK92 Cells: An Off-the-Shelf Cell Therapy for Cancer8
MM-459 Safety and Clinical Activity of Belantamab Mafodotin With Lenalidomide Plus Dexamethasone in Patients With Relapsed/Refractory Multiple Myeloma (RRMM): DREAMM-6 Arm-A Interim Analysis8
EXABS-147-AML How Do We Overcome Resistance to Venetoclax8
MM-530 Interventions and Outcomes of Multiple Myeloma Patients Progressing after BCMA-Targeted Chimeric Antigen Receptor (CAR) T-Cell Therapy8
Poster: MM-474 Minimal Residual Disease Perception and Utilization in Real-World Multiple Myeloma Treatment8
P-100: Allosteric HSP70 inhibitors perturb mitochondrial proteostasis and overcome proteasome inhibitor resistance in multiple myeloma8
P-019: Correlative analysis to define patient profiles associated with manufacturing and clinical endpoints in relapsed/refractory multiple myeloma patients treated with idecabtagene vicleucel (ide-ce8
MDS-556 Comparison of Demographics, Disease Characteristics and Outcomes Between Black and White Patients With Myelodysplastic Syndrome: A Population-Based Study8
AML-156 Early Deaths in Patients With Newly Diagnosed Acute Promyelocytic Leukemia: A Single-Center Retrospective Study From a General Hospital8
CLL-240 Frequency of IKZF3 L162R Mutation in B-Cell Lymphoproliferative Disorders8
CLL-410 Adherence and Discontinuation Among Medicare Beneficiaries Initiating Venetoclax versus BTKis for Relapsed/Refractory Chronic Lymphocytic Leukemia8
Poster: TCL-084 Subcutaneous Panniculitis-Like T-Cell Lymphoma With Co-Existing Lupus Panniculitis: A Case Report8
P-001: RNA-sequencing reveals transcriptomic similarity of AL amyloidosis and MGUS aberrant plasma cells along with several potential ALA target candidate genes8
MM-369 Clinical Diversity of Multiple Myeloma Over Time, From First Presentation to Diagnosis, in Kurdistan Region, Iraq8
P-206: Antibodies to omicron variants are maintained in newly diagnosed MM patients on lenalidomide, cyclophosphamide, bortezomib and dexamethasone (RCyBorD): results from the UK RADAR/Myeloma XV Tria8
EXABS-134-ALL Dual CAR T-Cell for ALL8
Poster: CLL-517 Hypertension as an Adverse Event of Ibrutinib: Does Age Matter?7
POSTER: ABCL-501 Treatment of Mediastinal Gray Zone Lymphoma After Progression on First-Line Therapy Including Rituximab: Treatment With High-Dose Therapy, Nivolumab and Ipilimumab7
SOHO State of the Art Updates and Next Questions: BTK inhibitors combined with chemoimmunotherapy in CLL, the best of both worlds?7
MM-145: Clinical characteristics and molecular genetic factors in patients with extramedullar bone lesions7
ORAL ABSTRACT: ALL-712 Can Chimeric Antigen Receptor T-Cell Therapy Be a Definitive Treatment for Adult Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia Without Stem Cell Transplant? Long-Term 7
IBCL-341: Fixed-Duration Subcutaneous Mosunetuzumab in Patients With Previously Untreated High-Tumor Burden Follicular Lymphoma (FL): Interim Results From the Phase 2 MorningSun Study7
Poster: ABCL-523 Immunohistochemical (IHC) Expression of Epigenetic Regulators (EZH-2 and H3K27) as well as Cell Cycle Regulators (P16, P53 and RB) in Patients Diagnosed With Primary Diffuse Large B-C7
AML-327 Novel Anti–B7-H3 Blocking Antibody Enhances NK Cell–Mediated Cytotoxicity and Improves Outcomes in AML-Bearing Mice7
Poster: CT-329 CD19-Directed Chimeric Antigen Receptor T Cell Therapy in Waldenström Macroglobulinemia: Initial Experience in Two Clinical Trials7
A Phase 2 Study of PNT2258 for Treatment of Relapsed or Refractory B-Cell Malignancies7
MM-101: Iberdomide (IBER), Daratumumab (DARA), and Dexamethasone (DEX) (IberDd) in Transplant-Ineligible (TNE) Newly Diagnosed Multiple Myeloma (NDMM): Results From the Phase 1/2 CC-220-MM-001 Trial7
MM-547: Role of IL10 Single-Nucleotide Variation in Multiple Myeloma7
EXABS-176-AML: How to Best Incorporate FLT3 Inhibitors in the Management of FLT3-Mutated AML7
ALL-031: Outcome of Adult Acute Lymphoblastic Leukemia: A Single-Center Experience7
POSTER: ABCL-755 Phase 1 Study of ARV-393, a PROTAC BCL6 Degrader, in Advanced Non-Hodgkin Lymphoma (NHL)7
Poster: CT-195 Predictive Value of ST2, REG3a, and MAGIC Algorithm in Haploidentical Transplantation With Post-Transplant Cyclophosphamide Outcomes7
A Prospective Economic Analysis of Early Outcome Data From the Alliance A041202/ CCTG CLC.2 Randomized Phase III Trial Of Bendamustine-Rituximab Compared With Ibrutinib-Based Regimens in Untreated Old7
TCL-1382: Evaluating Mortality Trends and Disparities Related to T-Cell Lymphomas Among Adults in the United States: A Retrospective Analysis of Two Decades7
POSTER: AML-983 Evaluating ChatGPT’s Responses to Commonly AskedQuestions in Allogeneic Hematopoietic Stem Cell Transplantation: A Physician-Based Assessment7
POSTER: MM-846 Global Disparities in Multiple Myeloma Outcomes: A World Health Organization Region-Based Analysis of Survival Proxies and Health System Indicators7
CLL-563: Bexobrutideg (NX-5948), a Novel Bruton's Tyrosine Kinase Degrader, Demonstrates Rapid and Durable Clinical Responses in Relapsed/Refractory Chronic Lymphocytic Leukemia: Updated Findings from7
TCL-306 Application of the Proposed Immunohistochemistry Algorithm for the Prognostication of GATA3 and TBX21 Subtypes of Peripheral T-Cell Lymphoma, Not Otherwise Specified7
HL-439: Superadded HLH in a Child With Hodgkin Lymphoma and Concurrent EBV Viremia: Case Report6
AML-666: Mutational Landscape of the RTK-RAS Signaling Pathway in Acute Myeloid Leukemia: Insights From Whole-Exome Sequencing6
TCL-1041: Aggressive CD56-Negative T-Cell Large Granular Lymphocyte Leukemia With Liver Infiltration in a Young Adult: A Rare Case Report6
POSTER: CLL-773 Real-World Outcomes of BTK Inhibitors (BTKi) in Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) Patients With Preexisting Cardiovascular Comorbidities6
POSTER: ABCL-475 5-Year Analysis of the POLARIX Study: Prolonged Follow-Up Confirms Positive Impact of Polatuzumab Vedotin Plus Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone (Pola-R-CHP) on6
ALL-852: Retrospective Analysis of Hepatotoxicity Associated With Inotuzumab Therapy in B-Cell Acute Lymphoblastic Leukemia: Describing a New Clinical Phenomenon Called Calicheamicin Syndrome6
ABCL-1061: Prevalence and Clinical Outcomes of Hepatitis B Virus Seropositivity in Lymphoma Patients Undergoing Rituximab-Based Therapy6
MCL-365: Mantle Cell Lymphoma and Cisplatin-Induced Hyponatremia: A Case Report6
Outcomes of Teclistamab (Tec) Step-Up Dosing in Outpatient/Hybrid Settings Among a Large Sample of Relapsed Refractory Multiple Myeloma (RRMM) Patients Treated with Tec6
POSTER: MDS-307 Acquired Platelet Dysfunction Secondary to Myelodysplastic Syndrome: Successful Resolution With Syndrome-Directed Therapy6
POSTER: AML-995 QuANTUM-Wild: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Trial of Quizartinib in Combination With Chemotherapy and as Single-Agent Maintenance in FLT3-ITD–Negative Acute M6
Assessing the Clinical Implications and Prognostic Value of Light-Chain N-Glycosylation in 781 Multiple Myeloma Patients at Diagnosis6
POSTER: AML-114 All-Trans Retinoic Acid and Arsenic Trioxide versus All-Trans Retinoic Acid and Chemotherapy in Acute Promyelocytic Leukemia: A Meta-Analysis of Randomized Controlled Trials6
BCMA CAR T-Cell Therapy in Newly Diagnosed Transplant-ineligible Multiple Myeloma: An Open Label, Single-arm, Phase 2 Study (CAREMM-001)6
Exploring Molecular Glues to Activate Proteasomes and Develop Shared and Personalized Neoantigen-Based Therapeutics in Multiple Myeloma6
MPN-524: Phase 3 Study Comparing Ropeginterferon Alfa-2b With Anagrelide As Second-Line Treatment for Essential Thrombocythemia: SURPASS-ET Trial6
POSTER: ABCL-167 Post-Transplant Lymphoproliferative Disorder: Key Considerations and Real-World Analysis in a University Hospital in Northeastern Brazil6
HL-477: Who Should We Screen for Germline Cancer Predisposition in Pediatric Lymphoma?6
MPN-537: Decoding Myeloid Neoplasms: The Transformative Role of Next-Generation Sequencing in Hematology Oncology—Real-World Data From Resource-Constrained Settings6
POSTER: MPN-1441 Thrombosis Before Diagnosis: A 22-Year National Analysis of Missed Opportunities in Polycythemia Vera and Essential Thrombocythemia6
AML-1467: Adiposity-Driven Leukemogenesis: Global Trends in Acute Myeloid Leukemia Attributable to High BMI Across 204 Countries (1990–2021)6
POSTER: CLL-1245 Longitudinal Single-Cell Profiling of CLL Patients Exposed to BTK and BCL2 Inhibitors6
MM-1377: Balancing Efficacy and Safety: Apixaban vs Rivaroxaban in Multiple Myeloma-Associated Thrombosis and Clinical Outcomes6
POSTER: IBCL-416 Treatment Preferences of Patients, Caregivers, and Physicians in Follicular Lymphoma (FL): A Global Discrete-Choice Experiment (DCE) Study6
CLL-1044: Beyond the Stage: The Evolving Landscape of Cytogenetic Risk in African Americans With CLL and Its Impact on Clinical Strategies6
AML-976: V-RULES: Impact of Treatment Setting on CPX-351 Safety and Effectiveness in Secondary Acute Myeloid Leukemia6
Composition and Functional State of T and NK Cells in Extramedullary Myeloma Tumor Microenvironment6
POSTER: AML-1290 Outcomes in Patients Younger Than 50 Years Old (yo) With Treatment-Naive Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) Treated With Tagraxofusp: Subanalysis of a Phase 1/2 Tria6
POSTER: AML-481 Treatment Outcomes of All-Trans Retinoic Acid, Arsenic Trioxide, and Daunorubicin in High-Risk Pediatric Acute Promyelocytic Leukemia: A Single-Center Study From a Quaternary Care Cent6
The Value of Progression-Free Survival (PFS) from the Perspectives of Patients with Multiple Myeloma (MM) and Treating Physicians: Quantitative Research Findings from Eight Countries6
POSTER: CT-929 Resolution of Infectious Episodes Through Surgical Interventions in Severely Neutropenic and Thrombocytopenic Patients6
IBCL-783: High CR and MRD Negativity Rates With GLPG5101, a Fresh, Stem-Like, Early Memory CD19 CAR T With 7-Day Vein-to-Vein Time: Full Results From ATALANTA-1 Cohort 3 (iNHL)6
MDS-1306: Survival Trends and Prevalence Disparities in Refractory Anemia With Ringed Sideroblasts6
POSTER: CT-1454 CAR T-Cell Therapy in the Treatment of Relapsed/Refractory Aggressive B-Cell Lymphomas6
MCL-1122: A SEER Study on Incidence and Survival Trends in Mantle Cell Lymphoma Involving Tonsils6
CT-1338: Impact of Depression on In-Hospital Outcomes Among Patients Undergoing Bone Marrow Transplantation: A National Inpatient Sample Analysis6
CT-696: Results of Low-Dose Cyclophosphamide in GVHD Prevention After Allo-HSCT for Acute Leukemia in Uzbekistan6
MM-1419: Pooled Incidence of Cytokine Release Syndrome in Talquetamab Therapy for Relapsed/Refractory Multiple Myeloma: A Systematic Review6
Cevostamab Plus Pomalidomide (Pom) and Dexamethasone (dex) in Relapsed/Refractory Multiple Myeloma (RRMM): Phase I Dose-Expansion Results from the CAMMA 1 Study6
POSTER: CT-087 Preliminary Insights into CAR-T Therapy for Melanoma: A Systematic Review6
POSTER: CLL-950 Chronic Lymphocytic Leukemia Mortality in the US (1999–2023): A National Analysis From CDC WONDER6
AML-1252: Equitable Overall Survival in AML With Hypomethylating Agent and Venetoclax Despite Medically Underserved Area or Driving Distance: A Comparative Cohort Analysis Including Intensive Chemothe6
POSTER: MCL-611 Complete Response in Heavily Pretreated Refractory Mantle Cell Lymphoma After Bendamustine and Glofitamab: A Paradigm Shift in Immunotherapy Sequencing6
ALL-160: A Retrospective Analysis of Molecular Markers in Patients Diagnosed With Acute Lymphoblastic Leukemia in 4 Consecutive Years—A Single-Center Experience6
POSTER: CML-1112 Pregnancy Outcomes in Women With Chronic Myeloid Leukemia: A Single-Center Experience From Pakistan6
POSTER: ABCL-361 Time-Limited Antithrombotic Prophylaxis Reduces the Risk of PICC-Related Thrombosis in Patients With Aggressive B-Cell Lymphoma Receiving DAEPOCH-R6
EXABS-230-ABCL: Potential of AI Remote Patient Monitoring for Lymphoma6
CALM: A Deep Learning Time Series Model for Predicting Progression from Smoldering Multiple Myeloma Using Clinical Data6
MM-718: Lisaftoclax (APG-2575) Combined With Novel Therapeutic Regimens in Patients With Relapsed or Refractory (R/R) Multiple Myeloma (MM) or Immunoglobulin Light-Chain (AL) Amyloidosis6
MPN-1333: Essential Thrombocythemia (ET) Presenting as Bilateral Adrenal Hemorrhage in an Older Adult Patient: A Rare Clinical Manifestation of a Myeloproliferative Neoplasm (MPN)6
CLL-1397: Genetic and Mutational Characterization in Patients With Chronic Lymphocytic Leukemia at the Guatemalan Social Security Institute6
MM-034 PDL-1 expression in Multiple Myeloma Patients Associated with Systemic Lupus Erythematosus5
A Primary Pulmonary Determination—A Rare Form of Marginal B-Cell Lymphoma: A Case Report5
Corrigendum to P-207: A multi-center, phase 1b study to assess the safety, Pharmacokinetics and efficacy of subcutaneous Isatuximab plus Pomalidomide and Dexamethasone, in patients with Relapsed/Refra5
P-267 Teclistamab is safe and effective in relapse refractory multiple myeloma patients with end stage renal disease: a case series5
P-333 Multi-omic analysis of multiple myeloma subtypes reveals epigenetic programs of high-risk disease5
SOHO State of the Art Updates and Next Questions | Approach to Older Adults With Phildadelphia-Chromosome Negative Acute Lymphoblastic Leukemia5
Evaluation of Clinical Characteristics and Prognostic Factors of Early Progressive Disease (EPD) in Newly Diagnosed Multiple Myeloma Patients: Real-World Data of the Greek Myeloma Study Group5
Otolaryngologist's Approach to Acute Purulent Tonsillitis as an Early Symptom of Lymphoma5
Predictors and Outcomes of Clostridioides difficile Infection in Hematopoietic Stem Cell Transplant: A National Readmission Database Analysis, 2018-20205
CLL-950: Chronic Lymphocytic Leukemia Mortality in the US (1999–2023): A National Analysis From CDC WONDER5
P-262 Retreatment with previously refractory drugs in multiple myeloma5
P-287 Isatuximab plus pomalidomide and dexamethasone in patients with relapsed and/or refractory multiple myeloma in real life context in France: IMAGE subgroup analysis based on subgroups of interest5
Treatment Pattern, Healthcare Resource Utilization and Symptom Burden Among Patients with Triple Class Exposed Multiple Myeloma: A Population-Based Cohort Study5
P-372 Transcriptomic expression of BMP-2, BMP-6 and Smad6 genes in newly diagnosed and relapsed multiple myeloma patients5
IBCL-094 A Primary Pulmonary Determination—A Rare Form of Marginal B-Cell Lymphoma: A Case Report5
Table of Contents5
P-373 Functional genomics of genes residing in the minimally deleted chromosome 17p13 region in multiple myeloma: therapeutic implications5
P-240 Efficacy and safety of ciltacabtagene autoleucel in patients with relapsed/refractory multiple myeloma and prior noncellular anti-BCMA therapy: CARTITUDE-2 cohort C5
Efficacy and Safety of Regimens Used for the Treatment of POEMS Syndrome- A Systematic Review5
SOHO State of the Art Updates and Next Questions | Choosing the Best Frontline BCR::ABL1 Tyrosine Kinase Inhibitor in Chronic Myeloid Leukemia—How to Define the Treatment Value?5
0.16121315956116